RIPK2 and irritable bowel syndrome: Interestingly, with respect to the activation of RIPK2, standard IBD drug treatment does not appear to resolve the issue of abnormal RIPK2 activation (Figure 5C), nor does clinical remission reflect changes in RIPK2 activity (Figure 5D).